Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Intuitive Surgical Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Accounts payable	291,200)	266,800)	276,200)	193,400)	218,700)	194,400)	194,400)	188,700)	196,200)	199,700)	164,100)	147,000)	164,200)	149,700)	128,100)	121,200)	120,000)	117,900)	103,100)	81,600)	116,000)	108,900)	133,400)
Accrued compensation and employee benefits	455,500)	420,800)	309,700)	535,600)	377,500)	321,300)	238,400)	436,400)	374,800)	346,600)	260,900)	401,600)	308,200)	278,600)	219,800)	350,100)	265,300)	254,000)	194,800)	235,000)	175,200)	168,700)	156,500)
Deferred revenue	491,100)	499,900)	496,300)	468,800)	426,000)	433,900)	437,500)	446,100)	394,800)	405,200)	417,800)	397,300)	358,900)	376,300)	386,000)	377,200)	348,500)	360,000)	358,100)	350,300)	327,800)	343,100)	337,400)
Other accrued liabilities	565,400)	505,100)	455,900)	547,500)	654,600)	537,900)	504,800)	587,500)	710,600)	586,900)	464,600)	476,200)	402,100)	370,400)	378,300)	301,300)	293,500)	272,700)	248,600)	298,300)	275,700)	304,100)	318,600)
Current liabilities	1,803,200)	1,692,600)	1,538,100)	1,745,300)	1,676,800)	1,487,500)	1,375,100)	1,658,700)	1,676,400)	1,538,400)	1,307,400)	1,422,100)	1,233,400)	1,175,000)	1,112,200)	1,149,800)	1,027,300)	1,004,600)	904,600)	965,200)	894,700)	924,800)	945,900)
Other long-term liabilities	506,500)	517,500)	474,600)	468,300)	389,100)	365,900)	406,500)	385,500)	412,800)	405,200)	451,600)	439,300)	453,400)	447,800)	409,300)	453,700)	447,800)	412,900)	445,600)	444,600)	436,100)	412,400)	414,700)
Long-term liabilities	506,500)	517,500)	474,600)	468,300)	389,100)	365,900)	406,500)	385,500)	412,800)	405,200)	451,600)	439,300)	453,400)	447,800)	409,300)	453,700)	447,800)	412,900)	445,600)	444,600)	436,100)	412,400)	414,700)
Total liabilities	2,309,700)	2,210,100)	2,012,700)	2,213,600)	2,065,900)	1,853,400)	1,781,600)	2,044,200)	2,089,200)	1,943,600)	1,759,000)	1,861,400)	1,686,800)	1,622,800)	1,521,500)	1,603,500)	1,475,100)	1,417,500)	1,350,200)	1,409,800)	1,330,800)	1,337,200)	1,360,600)
Preferred stock, $0.001 par value, issuable in series; zero shares issued and outstanding	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Common stock, $0.001 par value	400)	400)	400)	400)	400)	400)	400)	400)	400)	400)	400)	400)	400)	400)	400)	400)	400)	100)	100)	100)	100)	100)	100)
Additional paid-in capital	10,478,800)	10,236,800)	9,993,700)	9,681,300)	9,440,200)	9,149,700)	8,903,000)	8,576,400)	8,385,900)	8,150,800)	7,928,400)	7,703,900)	7,684,800)	7,484,000)	7,354,600)	7,164,000)	7,015,100)	6,804,400)	6,627,300)	6,445,200)	6,304,300)	6,085,100)	5,926,800)
Retained earnings	6,424,000)	7,605,500)	7,139,400)	6,803,300)	6,129,800)	5,581,700)	5,067,900)	4,743,000)	4,209,200)	3,807,700)	3,397,400)	3,500,100)	4,017,800)	4,682,800)	4,858,000)	4,760,900)	4,390,100)	4,022,700)	3,514,700)	3,261,300)	2,937,200)	2,633,000)	2,570,900)
Accumulated other comprehensive income (loss)	26,500)	3,000)	(27,100)	(51,300)	12,900)	(23,500)	(8,700)	(12,200)	(56,500)	(79,800)	(108,500)	(162,500)	(187,600)	(144,200)	(110,700)	(24,200)	5,300)	10,300)	11,400)	24,900)	16,200)	22,300)	8,900)
Total Intuitive Surgical, Inc. stockholders’ equity	16,929,700)	17,845,700)	17,106,400)	16,433,700)	15,583,300)	14,708,300)	13,962,600)	13,307,600)	12,539,000)	11,879,100)	11,217,700)	11,041,900)	11,515,400)	12,023,000)	12,102,300)	11,901,100)	11,410,900)	10,837,500)	10,153,500)	9,731,500)	9,257,800)	8,740,500)	8,506,700)
Noncontrolling interest in joint venture	112,400)	107,400)	101,300)	95,900)	94,200)	88,200)	83,800)	89,700)	84,500)	80,600)	76,500)	70,700)	58,600)	59,400)	54,600)	50,400)	48,600)	42,000)	36,700)	27,600)	28,900)	25,900)	23,800)
Total stockholders’ equity	17,042,100)	17,953,100)	17,207,700)	16,529,600)	15,677,500)	14,796,500)	14,046,400)	13,397,300)	12,623,500)	11,959,700)	11,294,200)	11,112,600)	11,574,000)	12,082,400)	12,156,900)	11,951,500)	11,459,500)	10,879,500)	10,190,200)	9,759,100)	9,286,700)	8,766,400)	8,530,500)
Total liabilities and stockholders’ equity	19,351,800)	20,163,200)	19,220,400)	18,743,200)	17,743,400)	16,649,900)	15,828,000)	15,441,500)	14,712,700)	13,903,300)	13,053,200)	12,974,000)	13,260,800)	13,705,200)	13,678,400)	13,555,000)	12,934,600)	12,297,000)	11,540,400)	11,168,900)	10,617,500)	10,103,600)	9,891,100)

Accounts payable: Accounts payable displayed moderate fluctuations with a general upward trend from early 2020 through late 2025. Initially around 133.4 million USD in Q1 2020, it dipped to approximately 81.6 million USD by Q4 2020, then steadily increased to reach a peak nearing 291.2 million USD by Q3 2025.
Accrued compensation and employee benefits: This liability exhibited considerable volatility. Starting at 156.5 million USD in Q1 2020, it peaked multiple times, notably 535.6 million USD in Q4 2024, before settling slightly lower around 455.5 million USD by Q3 2025. The pattern suggests significant variations in accrued employee-related expenses.
Deferred revenue: Deferred revenue remained relatively stable with modest growth over the period. From 337.4 million USD in Q1 2020, it gradually increased to around 491.1 million USD by Q4 2025, reflecting consistent revenue recognition patterns and potential steady new order bookings.
Other accrued liabilities: These liabilities showed an upward trajectory, rising from 318.6 million USD in Q1 2020 to a peak exceeding 710.6 million USD by Q3 2023, before fluctuating and settling around 565.4 million USD by Q3 2025. This indicates an overall increase in miscellaneous obligations.
Current liabilities: Current liabilities followed a general increasing trend across the reporting periods, starting at roughly 945.9 million USD in Q1 2020 and advancing to a high of 1.8 billion USD by Q3 2025. The increasing current liabilities reflect greater short-term obligations, possibly correlating with business growth or operational scale-up.
Other long-term liabilities and Long-term liabilities: Both categories were consistent, with values around 400 to 500 million USD throughout the period. Minor fluctuations were observed, but no clear upward or downward trend occurred, indicating relatively stable long-term obligations.
Total liabilities: Total liabilities experienced a growth trend over the five-year span. Beginning at approximately 1.36 billion USD in Q1 2020, the figure spiked to around 2.3 billion USD by Q3 2025. This rise aligns mainly with increases in current liabilities and accrued obligations.
Common stock: The par value of common stock remained mostly steady at 400 thousand USD from mid-2020 onward, suggesting no significant issuance or retirement of shares during the period.
Additional paid-in capital: This equity component demonstrated a steady increase from about 5.93 billion USD in Q1 2020 to approximately 10.48 billion USD by Q3 2025. The continuous rise indicates ongoing capital injections or retained capital enhancements.
Retained earnings: Retained earnings grew notably, from 2.57 billion USD in early 2020 to a peak near 7.6 billion USD by Q3 2025. Intermediate declines were seen around 2022 and early 2023, suggesting some periods of lower profitability or dividend payouts but overall substantial accumulation over time.
Accumulated other comprehensive income (loss): This item showed significant volatility, oscillating between positive and negative values. After positive balances in early 2020, a material decline into negative territory occurred around 2022, followed by a partial recovery by 2025. This pattern may reflect fluctuations in foreign currency translation adjustments or other comprehensive income components.
Total stockholders’ equity: Total stockholders’ equity increased steadily from about 8.53 billion USD in Q1 2020 to a high exceeding 17.9 billion USD by mid-2025, before a slight decline to roughly 17.0 billion USD by Q3 2025. The escalation corresponds with rises in paid-in capital and retained earnings.
Noncontrolling interest in joint venture: The noncontrolling interest expanded moderately, from approximately 23.8 million USD in early 2020 to 112.4 million USD by Q3 2025, indicative of growth or increased valuation in joint ventures.
Total liabilities and stockholders’ equity: This aggregate measure increased from about 9.89 billion USD in Q1 2020 to a peak near 20.16 billion USD by mid-2025, with a slight retreat by Q3 2025. This overall rise signals company growth in asset base matched by increasing liabilities and equity.

Download chart

Intuitive Surgical Inc. (NASDAQ:ISRG)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data